Cepheid Receives FDA Clearance for Xpert® Xpress GBS
Redesigned test introduces two new targets to improve coverage and sensitivity for Group B Streptococcus intrapartum testing for pregnant females
Group B Streptococcus (GBS) is the leading cause of newborn infection.
With the capability of returning positive results as early as 30 minutes,2 Xpert Xpress GBS can provide real-time GBS status and inform decisions about empiric antibiotic prophylaxis if appropriate, to prevent GBS transmission during birth.
"Up to 50% of colonized mothers may pass a Group B Streptococcus infection to their newborn baby, leading to an increased risk of early-onset neonatal sepsis,3" said
With Xpert Xpress GBS,
1 |
ACOG Guidelines: Prevention of Group B Streptococcal Early-Onset Disease in Newborns. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2020/02/prevention-of-group-b-streptococcal-early-onset-disease-in-newborns |
2 |
With early assay termination for positives only; reporting of negatives in approximately 42 minutes |
3 |
Blaser MJ et al., Infant antibiotic exposures and early-life body mass, Int J Obes (Lond). 2013 January ; 37(1): 16–23 |
US-IVD. In Vitro Diagnostic Medical Device.
About
Based in
For Cepheid Media Inquiries:
darwa.peterson@cepheid.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cepheid-receives-fda-clearance-for-xpert-xpress-gbs-302084992.html
SOURCE